Zenagamtide

Status

In trials. Not approved. Novo Nordisk reported phase 3 initiation planned for 2026.

What it is

A unimolecular GLP-1 and amylin agonist (formerly amycretin), studied as a weekly injection and a daily tablet; phase 3 planned for 2026.

What published research measured

Zenagamtide is the newer name for amycretin. Phase 2 trials in adults with type 2 diabetes reported HbA1c reductions against placebo at week 36 (Lancet 2026, PMID 42532080); Novo Nordisk's 2025 annual report gives reductions of up to 1.8 percentage points for the weekly injection, with 89% reaching HbA1c below 7%, and up to 1.5 points for the daily tablet, with 78%. Body weight was a secondary outcome. Novo Nordisk reported phase 3 initiation planned for 2026. Everything published so far is phase 2.

Source

Mora P et al. 2026 — Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist,… · Mora P et al. 2026 — Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults… · Oldenburg LIK et al. 2026 — Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide

Sources

• PubMed 42532080